Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

Investing $12,000 in the stock today would allow you to collect approximately $600 in dividends per year. Combined with the ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer acquired a smaller company for $4.9 billion to improve its prospects in the GLP-1 market. The pharmaceutical giant could carve out a small niche for itself in this growing space. Pfizer's ...

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...